0001193125-22-221861.txt : 20220816 0001193125-22-221861.hdr.sgml : 20220816 20220816084232 ACCESSION NUMBER: 0001193125-22-221861 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220815 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220816 DATE AS OF CHANGE: 20220816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001159036 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 880488686 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32335 FILM NUMBER: 221168582 BUSINESS ADDRESS: STREET 1: 11388 SORRENTO VALLEY ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121-1345 BUSINESS PHONE: (858) 794-8889 MAIL ADDRESS: STREET 1: 11388 SORRENTO VALLEY ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121-1345 FORMER COMPANY: FORMER CONFORMED NAME: HALOZYME THERAPEUTICS INC DATE OF NAME CHANGE: 20040312 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC DATE OF NAME CHANGE: 20010912 8-K 1 d335715d8k.htm 8-K 8-K
false 0001159036 0001159036 2022-08-15 2022-08-15

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 15, 2022

 

 

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Commission File Number 001-32335

 

Delaware   88-0488686

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

 

11388 Sorrento Valley Road  
San Diego  
California   92121
(Address of principal executive offices)   (Zip Code)

(858) 794-8889

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value   HALO   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01.

Other Events.

On August 15, 2022, Halozyme Therapeutics, Inc. (the “Company”) issued a press release announcing the upsize and pricing of its offering of convertible senior notes due 2028 in an aggregate principal amount of $625.0 million (the “Notes”). The Company also offered to grant to the initial purchasers of the Notes an option to purchase up to an additional $95.0 million aggregate principal amount of the Notes. The Notes will be sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.		   

Description

99.1    Press release dated August 15, 2022.
104    Inline XBRL for the cover page of this Current Report on Form 8-K.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    HALOZYME THERAPEUTICS, INC.
August 16, 2022     By:  

/s/ Nicole LaBrosse

    Name:   Nicole LaBrosse
    Title:  

Senior Vice President and Chief

Financial Officer

 EX-99.1 2 d335715dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

FOR IMMEDIATE RELEASE

Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of

$625 Million of Convertible Senior Notes due 2028

SAN DIEGO, CA (August 15, 2022) — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $625.0 million aggregate principal amount of convertible senior notes due 2028 (the “Convertible Notes”). The Convertible Notes are being offered and sold to “qualified institutional buyers” pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from an originally announced $500 million in aggregate principal amount. The Company also granted a 13-day option to the initial purchasers to purchase up to an additional $95.0 million aggregate principal amount of Convertible Notes.

The Convertible Notes will be senior, unsecured obligations of the Company and will accrue interest payable semi-annually in arrears at an annual rate of 1.00%. The Convertible Notes have an initial conversion rate of 17.8517 shares of the Company’s common stock per $1,000 principal amount of Convertible Notes (which is equivalent to an initial conversion price of approximately $56.02 per share of the Company’s common stock, representing an initial conversion premium of approximately 30% above the closing price of $43.09 per share of the Company’s common stock on August 15, 2022). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. Holders of the Convertible Notes will have the right to require the Company to repurchase all or a portion of their Convertible Notes upon the occurrence of a fundamental change (as defined in the indenture governing the Convertible Notes) at a cash repurchase price of 100% of their principal amount plus any accrued and unpaid interest. The Convertible Notes will mature on August 15, 2028, unless earlier redeemed, repurchased or converted in accordance with their terms prior to such date. Prior to the close of business on the business day immediately preceding February 15, 2028, the Convertible Notes will be convertible only upon the satisfaction of certain conditions and during certain periods, and on and after February 15, 2028, at any time prior to the close of business on the second scheduled trading day immediately preceding the maturity date, the Convertible Notes will be convertible regardless of these conditions. The Company will settle conversions in cash and, if applicable, shares of the Company’s common stock. The Company expects to close the offering on August 18, 2022, subject to the satisfaction of various customary closing conditions.

In connection with the pricing of the Convertible Notes, the Company entered into capped call transactions with certain of the initial purchasers of the Convertible Notes and/or their respective affiliates and/or other financial institutions (collectively, the “Capped Call Counterparties”). The capped call transactions are expected generally to reduce potential dilution to holders of the Company’s common stock on any conversion of the Convertible Notes or at the Company’s election (subject to certain conditions) offset any cash payments the Company is required to make in excess of the principal amount of any such converted Convertible Notes, as the case may be, with such reduction or offset subject to a cap based on the cap price. The cap price of the capped call transactions is initially $75.41 per share of the Company’s common stock, representing a premium of 75% above the last reported sale price of $43.09 per share of the Company’s common stock on August 15, 2022, and is subject to certain adjustments under the terms of the capped call transactions.

In connection with establishing their initial hedges of the capped call transactions, the Capped Call Counterparties or their respective affiliates may purchase shares of the Company’s common stock or enter into various derivative transactions with respect to the Company’s common stock concurrently with, or shortly after, the pricing of the Convertible Notes. This activity could increase (or reduce the size of any decrease in) the market price of the Company’s common stock or the Convertible Notes at that time.

In addition, the Capped Call Counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to the Company’s common stock or purchasing or selling the Company’s common stock in secondary market transactions following the pricing of the Convertible Notes and prior to the maturity of the Convertible Notes (and are likely to do so during the relevant valuation period under the capped

LOGO

 

call transactions or following any early conversion of the Convertible Notes or repurchase of the Convertible Notes by the Company on any fundamental change repurchase date, any redemption date or otherwise, in each case if the Company exercises its option to terminate the relevant portion of the capped call transactions). This activity could also cause or avoid an increase or decrease in the market price of the Company’s common stock or the Convertible Notes, which could affect noteholders’ ability to convert the Convertible Notes and, to the extent the activity occurs during any observation period related to a conversion of the Convertible Notes, it could affect the amount and value of the consideration that noteholders will receive on conversion of such Convertible Notes.

The Company will receive net proceeds from the offering of approximately $608.7 million (or approximately $701.4 million if the initial purchasers exercise their option to purchase additional Convertible Notes in full). The Company expects to use approximately $60.0 million of the net proceeds of the offering to fund the cost of entering into the capped call transactions. The Company also expects to use approximately $77.6 million of the net proceeds of the offering to enter into privately negotiated agreements with certain holders of its outstanding 1.25% convertible senior notes due 2024 (the “Existing Convertible Notes”) to exchange their Existing Convertible Notes for a combination of cash and shares of its common stock through privately negotiated transactions entered into concurrently with or shortly after the offering (the “Note Repurchases”). In connection with the Note Repurchases, the Company expects to pay approximately $77.6 million in cash, which includes accrued interest, and issue approximately 1.51 million shares of its common stock, to settle such exchanges. In addition, the Company expects to use a portion of the net proceeds of the offering to repurchase shares of its common stock (the “Share Repurchases”) up to $200 million, concurrently with, or shortly after, the offering in privately negotiated transactions or otherwise, which may be effected through one or more of the initial purchasers or an affiliate thereof. The Company anticipates using approximately $90.0 million of the net proceeds of the offering to repurchase approximately 2.09 million of its shares concurrently with the closing of the Convertible Notes offering on August 18, 2022, with the remaining Share Repurchases thereafter. Further, the Company expects to use a portion of the net proceeds of the offering to repay all of its outstanding $250 million term loan facility due 2026. The Company intends to use the remainder of the net proceeds from the offering for general corporate purposes, including other repurchases of the Company’s common stock from time to time under the existing stock repurchase program, working capital, capital expenditures, potential acquisitions and strategic transactions. If the initial purchasers exercise their option to purchase additional notes, the Company intends to use a portion of the net proceeds from the sale of additional notes to fund the cost of entering into additional capped call transactions.

The Share Repurchases, if consummated in full, would represent an increase of $100 million of the previously planned share repurchases to be made in 2022 under the Company’s ongoing three-year $750 million share repurchase program, which was commenced and previously announced in 2021.

The Note Repurchases and Share Repurchases could increase (or reduce the size of any decrease in) the market price of Halozyme common stock or the Convertible Notes. We also expect that some existing noteholders may purchase or sell shares of the Company’s common stock in the market to hedge their exposure in connection with these transactions. The Note Repurchases, Share Repurchases and any associated hedging by holders could have affected or affect the market price of the Company’s common stock prior to, concurrently with or shortly after the pricing of the Convertible Notes, and could have also resulted in a higher effective conversion price for the Convertible Notes.

This press release is neither an offer to sell nor a solicitation of an offer to buy the Convertible Notes or the shares of the Company’s common stock issuable upon conversion of the Convertible Notes, if any, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offer of these securities will be made only by means of a private offering memorandum.

The offer and sale of the Convertible Notes and the shares of the Company’s common stock issuable upon conversion of the Convertible Notes, if any, have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

LOGO

 

Forward-looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the planned offering. Words such as “anticipates,” “estimates,” “expects,” “projects,” “forecasts,” “intends,” “plans,” “will,” “believes” and words and terms of similar substance used in connection with any discussion identify forward-looking statements. These forward-looking statements are based on management’s current expectations and beliefs about future events and are inherently susceptible to uncertainty and changes in circumstances. Except as required by law, the Company is under no obligation to, and expressly disclaims any obligation to, update or alter any forward-looking statements whether as a result of such changes, new information, subsequent events or otherwise. With respect to the planned offering, such uncertainties and circumstances include whether the Company will consummate the offering; and the use of the net proceeds from the offering. Various factors could also adversely affect the Company’s operations, business or financial results in the future and cause the Company’s actual results to differ materially from those contained in the forward-looking statements, including those factors discussed in detail in the “Risk Factors” sections contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022, which are filed with the Securities and Exchange Commission.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme’s commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 600,000 patient lives in post-marketing use in five commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED®, TLANDO™ and NOCDURNA® and partnered commercial products and ongoing product development programs with industry leading pharmaceutical companies including Teva Pharmaceutical, Covis Pharma, Pfizer and Idorsia Pharmaceuticals.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

EX-101.SCH 3 halo-20220815.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 halo-20220815_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 halo-20220815_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g335715image1.jpg GRAPHIC begin 644 g335715image1.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Aug. 15, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001159036
Document Type 8-K
Document Period End Date Aug. 15, 2022
Entity Registrant Name HALOZYME THERAPEUTICS, INC.
Entity File Number 001-32335
Entity Incorporation State Country Code DE
Entity Tax Identification Number 88-0488686
Entity Address, Address Line One 11388 Sorrento Valley Road
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 794-8889
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol HALO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d335715d8k_htm.xml IDEA: XBRL DOCUMENT 0001159036 2022-08-15 2022-08-15 false 0001159036 8-K 2022-08-15 HALOZYME THERAPEUTICS, INC. 001-32335 DE 88-0488686 11388 Sorrento Valley Road San Diego CA 92121 (858) 794-8889 false false false false Common Stock, $0.001 par value HALO NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d335715d8k.htm d335715dex991.htm halo-20220815.xsd halo-20220815_lab.xml halo-20220815_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d335715d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d335715d8k.htm" ] }, "labelLink": { "local": [ "halo-20220815_lab.xml" ] }, "presentationLink": { "local": [ "halo-20220815_pre.xml" ] }, "schema": { "local": [ "halo-20220815.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "halo", "nsuri": "http://www.halozyme.com/20220815", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d335715d8k.htm", "contextRef": "duration_2022-08-15_to_2022-08-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d335715d8k.htm", "contextRef": "duration_2022-08-15_to_2022-08-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-22-221861-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-221861-xbrl.zip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end